Paracelsian Inc (PRLN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jonathan Schonsheck who wrote (2265)	4/3/1997 8:19:00 PM
From: Hank	of 4342

Jonathan, You are right. It looks as though PN27.1 (aka AndroCar?) does in fact inhibit more than just prostrate cancer related kinases. Why then the focus on just prostrate cancer? They mention they intended to file an IND with the FDA but that's obviously no longer the case since they're going the dietary supplement route. I guess it is possible that what they refer to as PN27.1 is actually a mixture of several compounds rather than a single chemical entity whereas AndroCar is the purified component specific to prostrate kinases. Hard to tell for sure without some chemical structure data that would normally accompany a drug in development. But since the active ingredient is not patentable, they're not about to release that. My general guess, based on their page, is that AndroCar can indeed inhibit more than one type of kinase . Therefore, it could potentially be used to treat more than one type of cancer.. Perhaps they are focusing on prostrate cancer initially to keep things simple and avoid getting the FDA upset. As for it's ability to uplift a persons sense of well being, maybe that will be a selling point for people who are just depressed. I know I'd like to try it out:) Hank

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next